We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+33.89%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.72B
AUM Growth
-$71.4M
Cap. Flow
-$452M
Cap. Flow %
-16.6%
Top 10 Hldgs %
41.91%
Holding
86
New
16
Increased
22
Reduced
27
Closed
9
Avg Time Held
2.6 years
Top 10 Avg Time Held
1.3 years
Top 20 Avg Time Held
1.1 years

Top Buys

Rank Stock Value
1
SLN icon
Silence Therapeutics
SLN
+$44.1M
2
KROS icon
Keros Therapeutics
KROS
+$32.8M
3
FDMT icon
4D Molecular Therapeutics
FDMT
+$32.2M
4
CI icon
Cigna
CI
+$21.5M
5
IMNM icon
Immunome
IMNM
+$20.5M

Top Sells

Rank Stock Value
1
IMGN icon
Immunogen Inc
IMGN
+$487M
2
RYZB icon
RayzeBio, Inc. Common Stock
RYZB
+$115M
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$67.7M
4
KRYS icon
Krystal Biotech
KRYS
+$31.2M
5
CTLT icon
CATALENT, INC.
CTLT
+$25.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.54%
2 Industrials 2.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
VTYX icon
51
DELISTED
Ventyx Biosciences
VTYX
$11.9M 0.44%
2,164,126
+1,956,923
+944% +$8.95M
2022 Q3
6 quarters
ISRG icon
52
Intuitive Surgical
ISRG
$151B
$11.8M 0.43%
29,546
-24,712
-46% -$9.34M
2023 Q4
1 quarter
CYTK icon
53
Cytokinetics
CYTK
$8.89B
$11.3M 0.42%
+161,600
New +$12.5M
2024 Q1
0 quarters
DGX icon
54
Quest Diagnostics
DGX
$26.4B
$11.2M 0.41%
+83,849
New +$10.9M
2024 Q1
0 quarters
MCK icon
55
McKesson
MCK
$116B
$11.1M 0.41%
+20,707
New +$10.5M
2024 Q1
0 quarters
NUVB icon
56
Nuvation Bio
NUVB
$1.67B
$11M 0.4%
3,031,009
– –
2021 Q1
12 quarters
ELAN icon
57
Elanco Animal Health
ELAN
$11.8B
$11M 0.4%
+676,039
New +$10.6M
2024 Q1
0 quarters
BPMC icon
58
DELISTED
Blueprint Medicines
BPMC
$10.7M 0.39%
+113,060
New +$9.7M
2024 Q1
0 quarters
PEN icon
59
Penumbra
PEN
$12.7B
$9.96M 0.37%
44,613
-50,629
-53% -$12.5M
2022 Q3
6 quarters
RPTX icon
60
DELISTED
Repare Therapeutics
RPTX
$9.5M 0.35%
2,016,302
-132,446
-6% -$849K
2020 Q2
15 quarters
APLS icon
61
DELISTED
Apellis Pharmaceuticals
APLS
$9.11M 0.33%
+155,000
New +$9.88M
2024 Q1
0 quarters
STXS icon
62
Stereotaxis
STXS
$105M
$8.64M 0.32%
3,308,798
-93,645
-3% -$223K
2019 Q3
18 quarters
CABA icon
63
Cabaletta Bio
CABA
$263M
$7.55M 0.28%
442,826
-931,363
-68% -$20M
2019 Q4
17 quarters
LVTX icon
64
DELISTED
LAVA Therapeutics
LVTX
$6.91M 0.25%
2,074,372
– –
2021 Q1
12 quarters
ATRA icon
65
Atara Biotherapeutics
ATRA
$96.9M
$6.43M 0.24%
370,532
+6,274
+2% +$111K
2014 Q4
37 quarters
IVVD icon
66
Invivyd
IVVD
$197M
$6.4M 0.23%
1,440,725
– –
2021 Q3
10 quarters
RAPT icon
67
DELISTED
RAPT Therapeutics
RAPT
$5.95M 0.22%
82,800
+36,953
+81% +$5.14M
2022 Q1
8 quarters
ACIU icon
68
AC Immune
ACIU
$244M
$5.94M 0.22%
2,007,031
+7,031
+0.4% +$25.2K
2023 Q4
1 quarter
ESTA icon
69
Establishment Labs
ESTA
$1.83B
$5.82M 0.21%
+114,341
New +$4.59M
2024 Q1
0 quarters
ALLK icon
70
DELISTED
Allakos
ALLK
$4.35M 0.16%
3,451,076
-219,371
-6% -$341K
2018 Q3
22 quarters
XERS icon
71
Xeris Biopharma Holdings
XERS
$1.84B
$2.31M 0.08%
1,046,587
– –
2018 Q2
23 quarters
ACHL
72
DELISTED
Achilles Therapeutics
ACHL
$2.01M 0.07%
1,608,089
– –
2021 Q1
12 quarters
KLRS icon
73
Kalaris Therapeutics
KLRS
$52.1M
$1.44M 0.05%
82,955
– –
2020 Q3
14 quarters
ADAP
74
DELISTED
Adaptimmune Therapeutics
ADAP
$1.13M 0.04%
715,607
– –
2023 Q2
3 quarters
LAB icon
75
Standard BioTools
LAB
$258M
$1.12M 0.04%
+411,631
New +$994K
2024 Q1
0 quarters
1 2
3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2024 Portfolio in Review

As of Q1 2024, Redmile Group held 86 positions worth $2.72B, down 2.6% from $2.8B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Redmile Group withdrew a net $452M in Q1 2024, closing 9 positions and reducing 27 holdings. Its most notable exit was Immunogen Inc, an estimated $487M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier, followed by Industrials.

Against the trend, Redmile Group opened a new position in Silence Therapeutics worth $43.8M.

  • Redmile Group's largest Q1 2024 buy was Silence Therapeutics: 2,027,669 shares worth $43.8M.
  • Redmile Group added most to Immunome in Q1 2024, an estimated $20.5M increase.
  • Redmile Group's biggest Q1 2024 reduction was Krystal Biotech, cutting an estimated $31.2M.
  • Redmile Group fully exited Immunogen Inc in Q1 2024, selling an estimated $487M.
  • Redmile Group's ten largest holdings make up 42% of its $2.72B portfolio in Q1 2024.
  • Redmile Group opened 16 new positions and closed 9 in Q1 2024.
  • Redmile Group's portfolio value fell 2.6% quarter-over-quarter to $2.72B.

Based on Redmile Group's 13F filing for Q1 2024, filed 15 May 2024.